Mechanistically, IL-27 activates the STAT3-mTOR signaling pathway in obese mice, promoting the synthesis and secretion of GLP-1 in the gut, thereby reducing insulin resistance and alleviating glucose and lipid metabolism disorders associated with obesity (126) (Table 2; Figure 2). Here, IL27 is linked to obesity disorder.